NCT02052219View on ClinicalTrials.gov

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2021

Conditions
IgA Nephropathy
Interventions
DRUG

Blisibimod

Blisibimod administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT02052219 - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy | Biotech Hunter | Biotech Hunter